Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.
240 medicines
-
Mirikizumab Being discontinued 2 products · updated December 22, 2025
Gastroenterology, Other
Product Availability Expected supply / notes Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)
Eli Lilly and Co.A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.
Being discontinued · December 22, 2025Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)
Eli Lilly and Co.A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
Being discontinued · December 22, 2025 -
Carbamazepine Being discontinued 3 products · updated December 19, 2025
Neurology
Product Availability Expected supply / notes Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)
Takeda Pharmaceuticals USA Inc.Discontinuation of the manufacture of the drug
Being discontinued · December 19, 2025Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)
Takeda Pharmaceuticals USA Inc.Discontinuation of the manufacture of the drug
Being discontinued · December 19, 2025Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)
Takeda Pharmaceuticals USA Inc.Discontinuation of the manufacture of the drug
Being discontinued · December 19, 2025 -
Doxercalciferol Being discontinued 3 products · updated December 10, 2025
Endocrinology/Metabolism
Product Availability Expected supply / notes Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · December 10, 2025Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · December 10, 2025Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · December 10, 2025 -
Spironolactone Being discontinued 2 products · updated December 10, 2025
Cardiovascular
Product Availability Expected supply / notes Aldactone, Tablet, 100 mg (NDC 0025-1031-31)
Pfizer Inc.Discontinuation of the manufacture of the drug.
Being discontinued · December 10, 2025Aldactone, Tablet, 25 mg (NDC 0025-1001-31)
Pfizer Inc.Discontinuation of the manufacture of the drug.
Being discontinued · December 10, 2025 -
Ampicillin Sodium Being discontinued 5 products · updated December 8, 2025
Anti-Infective
Product Availability Expected supply / notes Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95)
Sandoz Inc.Discontinuation of private label only
Being discontinued · December 8, 2025Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92)
Sandoz Inc.Discontinuation of private label only
Being discontinued · December 8, 2025Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95)
Sandoz Inc.Discontinuation of private label only
Being discontinued · December 8, 2025Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95)
Sandoz Inc.Discontinuation of private label only
Being discontinued · December 8, 2025Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92)
Sandoz Inc.Discontinuation of private label only
Being discontinued · December 8, 2025 -
Calcitriol Being discontinued 2 products · updated December 4, 2025
Endocrinology/Metabolism
Product Availability Expected supply / notes Calcitriol, Capsule, .5 ug (NDC 0093-7353-01)
Teva Pharmaceuticals USA, Inc.A business decision was made to discontinue manufacture of the drug
Being discontinued · December 4, 2025Calcitriol, Capsule, .25 ug (NDC 0093-7352-01)
Teva Pharmaceuticals USA, Inc.A business decision was made to discontinue manufacture of the drug
Being discontinued · December 4, 2025 -
Posaconazole Being discontinued 1 product · updated December 2, 2025
Anti-Infective
Product Availability Expected supply / notes Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)
Merck Sharp & Dohme Corp.Discontinuation of the manufacture of the drug
Being discontinued · December 2, 2025 -
Nilutamide Being discontinued 2 products · updated December 1, 2025
Oncology
Product Availability Expected supply / notes Nilandron, Tablet, 150 mg (NDC 59212-111-14)
Advanz Pharma (US) Corp.Product to expire in March 2026; Discontinuation of the manufacture of the drug
Being discontinued · December 1, 2025Nilandron, Tablet, 150 mg (NDC 66993-212-38)
Advanz Pharma (US) Corp.Product to expire in March 2026; Discontinuation of the manufacture of the drug
Being discontinued · December 1, 2025 -
Phenoxybenzamine Hydrochloride Being discontinued 3 products · updated December 1, 2025
Cardiovascular
Product Availability Expected supply / notes Dibenzyline, Capsule, 10 mg (NDC 59212-001-02)
Advanz Pharma (US) Corp.Discontinuation of the manufacture of the drug
Being discontinued · December 1, 2025Dibenzyline, Capsule, 10 mg (NDC 66993-066-02)
Advanz Pharma (US) Corp.Discontinuation of the manufacture of the drug
Being discontinued · December 1, 2025Dibenzyline, Capsule, 10 mg (NDC 59212-001-01)
Advanz Pharma (US) Corp.Discontinuation of the manufacture of the drug
Being discontinued · December 1, 2025 -
Verapamil Hydrochloride Being discontinued 1 product · updated November 21, 2025
Cardiovascular
Product Availability Expected supply / notes Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 21, 2025 -
Anagrelide Hydrochloride Being discontinued 2 products · updated November 19, 2025
Hematology
Product Availability Expected supply / notes Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60)
Teva Pharmaceuticals USA, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60)
Teva Pharmaceuticals USA, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025 -
Hydrochlorothiazide Being discontinued 2 products · updated November 19, 2025
Cardiovascular
Product Availability Expected supply / notes Microzide, Capsule, 12.5 mg (NDC 0591-0347-01)
Teva Pharmaceuticals USA, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025Microzide, Capsule, 12.5 mg (NDC 0591-0347-05)
Teva Pharmaceuticals USA, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025 -
Valsartan Being discontinued 4 products · updated November 19, 2025
Cardiovascular
Product Availability Expected supply / notes Valsartan, Tablet, 80 mg (NDC 0378-5813-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyA business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025Valsartan, Tablet, 160 mg (NDC 0378-5814-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyA business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025Valsartan, Tablet, 40 mg (NDC 0378-5807-93)
Mylan Pharmaceuticals Inc., a Viatris CompanyA business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025Valsartan, Tablet, 320 mg (NDC 0378-5815-77)
Mylan Pharmaceuticals Inc., a Viatris CompanyA business decision was made to discontinue manufacture of the drug.
Being discontinued · November 19, 2025 -
Montelukast Sodium Being discontinued 1 product · updated November 17, 2025
Pulmonary/Allergy
Product Availability Expected supply / notes Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)
OrganonDiscontinuation of the manufacture of the drug
Being discontinued · November 17, 2025 -
Ceftazidime Being discontinued 2 products · updated November 14, 2025
Anti-Infective
Product Availability Expected supply / notes Tazicef, Injection, 2 g (NDC 0409-5093-11)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 14, 2025Tazicef, Injection, 1 g (NDC 0409-5092-16)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 14, 2025 -
Palonosetron Hydrochloride Being discontinued 1 product · updated November 14, 2025
Gastroenterology
Product Availability Expected supply / notes Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01)
Teva Pharmaceuticals USA, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 14, 2025 -
Somatropin Being discontinued 1 product · updated November 14, 2025
Endocrinology/Metabolism
Product Availability Expected supply / notes Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)
Novo Nordisk, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 14, 2025 -
Vancomycin Hydrochloride Being discontinued 1 product · updated November 14, 2025
Anti-Infective
Product Availability Expected supply / notes Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 14, 2025 -
Cetrorelix Acetate Being discontinued 1 product · updated November 13, 2025
Reproductive
Product Availability Expected supply / notes Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08)
Teva Pharmaceuticals USA, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 13, 2025 -
Guanfacine Being discontinued 4 products · updated November 13, 2025
Psychiatry
Product Availability Expected supply / notes Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11)
Actavis Pharma, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 13, 2025Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11)
Actavis Pharma, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 13, 2025Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11)
Actavis Pharma, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 13, 2025Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11)
Actavis Pharma, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · November 13, 2025 -
Calcium Chloride Being discontinued 1 product · updated November 7, 2025
Cardiovascular, Endocrinology/Metabolism
Product Availability Expected supply / notes Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34)
Hospira, Inc., a Pfizer CompanyDiscontinuation of the manufacture of the drug
Being discontinued · November 7, 2025 -
Deferiprone Being discontinued 1 product · updated November 7, 2025
Hematology
Product Availability Expected supply / notes Ferriprox, Tablet, 500 mg (NDC 10122-100-10)
Chiesi USA, Inc.Discontinuation of the manufacture of the drug.
Being discontinued · November 7, 2025 -
Ketamine Hydrochloride Being discontinued 1 product · updated November 7, 2025
Anesthesia
Product Availability Expected supply / notes Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 7, 2025 -
Acetaminophen; Oxycodone Hydrochloride Being discontinued 1 product · updated November 3, 2025
Analgesia/Addiction
Product Availability Expected supply / notes Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025 -
Atazanavir and Cobicistat Being discontinued 1 product · updated November 3, 2025
Antiviral
Product Availability Expected supply / notes Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)
Bristol Myers Squibb Co.The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
Being discontinued · November 3, 2025 -
Lasmiditan Being discontinued 6 products · updated November 3, 2025
Neurology
Product Availability Expected supply / notes Reyvow, Tablet, 50 mg (NDC 0002-4312-62)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 100 mg (NDC 0002-4491-62)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 50 mg (NDC 0002-4312-61)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 100 mg (NDC 0002-4491-08)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 50 mg (NDC 0002-4312-08)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025Reyvow, Tablet, 100 mg (NDC 0002-4491-61)
Eli Lilly and Co.A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Being discontinued · November 3, 2025 -
Oxycodone and Acetaminophen Being discontinued 5 products · updated November 3, 2025
Analgesia/Addiction
Product Availability Expected supply / notes Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · November 3, 2025 -
Scopolamine Transdermal System Being discontinued 1 product · updated November 3, 2025
Gastroenterology, Neurology, Other
Product Availability Expected supply / notes Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · November 3, 2025 -
Phenobarbital Being discontinued 8 products · updated October 31, 2025
Analgesia/Addiction, Neurology, Other
Product Availability Expected supply / notes Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32)
Endo Pharmaceuticals, Inc.Discontinuation of the manufacture of the drug
Being discontinued · October 31, 2025 -
Prazosin Hydrochloride Being discontinued 3 products · updated April 28, 2023
Cardiovascular
Product Availability Expected supply / notes Minipress, Capsule, 2 mg (NDC 0069-4370-71)
Pfizer Inc.Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
Being discontinued · April 28, 2023Minipress, Capsule, 1 mg (NDC 0069-4310-71)
Pfizer Inc.Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023
Being discontinued · April 28, 2023Minipress, Capsule, 5 mg (NDC 0069-4380-71)
Pfizer Inc.Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
Being discontinued · April 28, 2023
Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.
Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update November 1, 2026 02:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.